Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Migraine
Sort By
Newest First
1 / 1
1 / 1
Migraine
Biohaven Announces NURTEC® ODT Receives First Global Approval Outside the U.S. For Prevention of Migraine
Biohaven
PR-M12-21-01
December 13, 2021
Biohaven to Advance Vazegepant Into Phase 3 for Acute Migraine Treatment
Biohaven
PA1632
March 27, 2020
FDA Approval
Allergan Receives FDA Approval for Migraine Treatment
Allergan
PR-M01-20-NI-001
January 02, 2020
Clinical Results
Biohaven Achieves Positive Topline Results for Intranasal Migraine Treatment
Biohaven
PR-M12-19-NI-025
December 17, 2019
Drug Development
Draft ICER Report Questions Cost-Effectiveness of New Migraine Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M11-19-NI-004
November 12, 2019
Migraine Therapy
Mimicking Environmental Enrichment for Migraine Therapy
Yuan Zhang, Ph.D.
Seurat Therapeutics
PAP-Q3-19-CL-026
October 28, 2019
FDA Approval
FDA Approves New Treatment for Patients with Migraine
FDA
PR-M10-19-NI-023
October 15, 2019
Migraine Prevention
Eli Lilly Looking to Boost Sales of Migraine Med with New Data on Emergency Room Visits
David Alvaro, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-004
August 01, 2019
Legal
Amgen Looking to Exit Migraine Collaboration with Novartis
Nice Insight
PAO-M04-19-NI-015
April 10, 2019
Drug Development
EMA Committee Recommends Approval of Teva’s Anti-CGRP Treatment for Migraines
Emilie Branch
Pharma's Almanac
PAO-M02-19-NI-003
February 06, 2019
